CERE — Cerevel Therapeutics Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $7.66bn
- $7.01bn
- 39
- 16
- 95
- 48
Annual cashflow statement for Cerevel Therapeutics Holdings, fiscal year end - December 31st, millions except per share.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | |
| Standards: | — | USG | USG | USG | USG |
| Status: | fx Preliminary | Final | Final | Final | Final |
| Net Income/Starting Line | — | -152 | -225 | -352 | -433 |
| Depreciation | |||||
| Non-Cash Items | — | 16.2 | 28.5 | 25.4 | 68.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | — | 17.7 | 15.5 | 28.1 | 16.1 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | — | -118 | -179 | -293 | -342 |
| Capital Expenditures | — | -18.9 | -10.5 | -3.95 | -3.81 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -425 | -385 | 77.5 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | — | -18.9 | -436 | -389 | 73.7 |
| Financing Cash Flow Items | — | 441 | 30.9 | 37.1 | 31.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | — | 441 | 424 | 623 | 549 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | — | 304 | -191 | -58.8 | 280 |